Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) has announced it will host a virtual Key Opinion Leader (KOL) event on April 17, 2026, to discuss new insights on ATH434, its investigational therapy for multiple system atrophy (MSA). The event will feature presentations from leading neurology experts, including Dr. Vikram Khurana, Chief of the Division of Movement Disorders at Brigham and Women's Hospital and Harvard Medical School.
The company states the event will focus on recent clinical and biomarker data supporting ATH434's potential mechanism of action. ATH434 is an oral, brain-penetrant small molecule designed to inhibit pathological aggregation of alpha-synuclein, a protein implicated in MSA and Parkinson's disease, by restoring iron balance in the brain.
Alterity is currently conducting a Phase 2 clinical trial, the ATH434-201 study, to evaluate the safety, tolerability, and efficacy of ATH434 in patients with early-stage MSA. MSA is a rare, progressive, and fatal neurodegenerative disorder with no approved disease-modifying therapies.
The virtual event is scheduled for 11:00 AM ET on April 17, 2026. Interested parties can register through the investor relations section of Alterity's website. A replay will be made available following the live presentation.
